JP2008503504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503504A5 JP2008503504A5 JP2007516973A JP2007516973A JP2008503504A5 JP 2008503504 A5 JP2008503504 A5 JP 2008503504A5 JP 2007516973 A JP2007516973 A JP 2007516973A JP 2007516973 A JP2007516973 A JP 2007516973A JP 2008503504 A5 JP2008503504 A5 JP 2008503504A5
- Authority
- JP
- Japan
- Prior art keywords
- strontium
- medicament
- pharmaceutical composition
- use according
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 101100496858 Mus musculus Colec12 gene Proteins 0.000 claims 4
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229910052712 strontium Inorganic materials 0.000 claims 4
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 4
- 229910000018 strontium carbonate Inorganic materials 0.000 claims 4
- 229940013553 strontium chloride Drugs 0.000 claims 4
- 229910001631 strontium chloride Inorganic materials 0.000 claims 4
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims 4
- 159000000008 strontium salts Chemical class 0.000 claims 4
- 208000020084 Bone disease Diseases 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 208000015100 cartilage disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 claims 2
- 229910052917 strontium silicate Inorganic materials 0.000 claims 2
- UBXAKNTVXQMEAG-UHFFFAOYSA-L strontium sulfate Chemical compound [Sr+2].[O-]S([O-])(=O)=O UBXAKNTVXQMEAG-UHFFFAOYSA-L 0.000 claims 2
- QSQXISIULMTHLV-UHFFFAOYSA-N strontium;dioxido(oxo)silane Chemical compound [Sr+2].[O-][Si]([O-])=O QSQXISIULMTHLV-UHFFFAOYSA-N 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 206010061762 Chondropathy Diseases 0.000 claims 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 235000021554 flavoured beverage Nutrition 0.000 claims 1
- 235000012208 gluconic acid Nutrition 0.000 claims 1
- 239000000174 gluconic acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229940047908 strontium chloride hexahydrate Drugs 0.000 claims 1
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 claims 1
- KQAGKTURZUKUCH-UHFFFAOYSA-L strontium oxalate Chemical compound [Sr+2].[O-]C(=O)C([O-])=O KQAGKTURZUKUCH-UHFFFAOYSA-L 0.000 claims 1
- VUWAXXIHYHUOJV-TYYBGVCCSA-L strontium;(e)-but-2-enedioate Chemical compound [Sr+2].[O-]C(=O)\C=C\C([O-])=O VUWAXXIHYHUOJV-TYYBGVCCSA-L 0.000 claims 1
- VUWAXXIHYHUOJV-ODZAUARKSA-L strontium;(z)-but-2-enedioate Chemical compound [Sr+2].[O-]C(=O)\C=C/C([O-])=O VUWAXXIHYHUOJV-ODZAUARKSA-L 0.000 claims 1
- CPKHHOBKIQHTLE-UHFFFAOYSA-L strontium;1,2,2-trimethylcyclopentane-1,3-dicarboxylate Chemical compound [Sr+2].CC1(C)C(C([O-])=O)CCC1(C)C([O-])=O CPKHHOBKIQHTLE-UHFFFAOYSA-L 0.000 claims 1
- IUMOPUXDPFMEMV-UHFFFAOYSA-L strontium;2,3-dihydroxybutanedioate Chemical compound [Sr+2].[O-]C(=O)C(O)C(O)C([O-])=O IUMOPUXDPFMEMV-UHFFFAOYSA-L 0.000 claims 1
- RZDNXOOMMJEAFR-UHFFFAOYSA-L strontium;2-hydroxybutanedioate Chemical compound [Sr+2].[O-]C(=O)C(O)CC([O-])=O RZDNXOOMMJEAFR-UHFFFAOYSA-L 0.000 claims 1
- CCUZKVDGQHXAFK-UHFFFAOYSA-L strontium;2-hydroxypropanoate Chemical compound [Sr+2].CC(O)C([O-])=O.CC(O)C([O-])=O CCUZKVDGQHXAFK-UHFFFAOYSA-L 0.000 claims 1
- CRLDSNGPLRRUQU-UHFFFAOYSA-L strontium;butanedioate Chemical compound [Sr+2].[O-]C(=O)CCC([O-])=O CRLDSNGPLRRUQU-UHFFFAOYSA-L 0.000 claims 1
- USBIHMTWQAZQAG-UHFFFAOYSA-L strontium;ethanesulfonate Chemical compound [Sr+2].CCS([O-])(=O)=O.CCS([O-])(=O)=O USBIHMTWQAZQAG-UHFFFAOYSA-L 0.000 claims 1
- JKBSENMNXXOMSO-UHFFFAOYSA-L strontium;methanesulfonate Chemical compound [Sr+2].CS([O-])(=O)=O.CS([O-])(=O)=O JKBSENMNXXOMSO-UHFFFAOYSA-L 0.000 claims 1
- LVZZABGEQTZXHP-UHFFFAOYSA-L strontium;propanedioate Chemical compound [Sr+2].[O-]C(=O)CC([O-])=O LVZZABGEQTZXHP-UHFFFAOYSA-L 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- QGAPCDHPGCYAKM-UHFFFAOYSA-H tristrontium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QGAPCDHPGCYAKM-UHFFFAOYSA-H 0.000 claims 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 claims 1
- -1 vitamin D compound Chemical class 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400991 | 2004-06-25 | ||
| DKPA200400991 | 2004-06-25 | ||
| DKPA200401733 | 2004-11-10 | ||
| DKPA200401733 | 2004-11-10 | ||
| PCT/DK2005/000425 WO2006000224A2 (en) | 2004-06-25 | 2005-06-24 | Compositions comprising strontium and vitamin d and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012157477A Division JP2012193208A (ja) | 2004-06-25 | 2012-07-13 | ストロンチウムおよびビタミンｄを含む組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008503504A JP2008503504A (ja) | 2008-02-07 |
| JP2008503504A5 true JP2008503504A5 (enExample) | 2008-07-10 |
| JP5070046B2 JP5070046B2 (ja) | 2012-11-07 |
Family
ID=34972075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516973A Expired - Fee Related JP5070046B2 (ja) | 2004-06-25 | 2005-06-24 | ストロンチウムおよびビタミンｄを含む組成物およびその使用 |
| JP2012157477A Withdrawn JP2012193208A (ja) | 2004-06-25 | 2012-07-13 | ストロンチウムおよびビタミンｄを含む組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012157477A Withdrawn JP2012193208A (ja) | 2004-06-25 | 2012-07-13 | ストロンチウムおよびビタミンｄを含む組成物およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8658206B2 (enExample) |
| EP (1) | EP1768748B2 (enExample) |
| JP (2) | JP5070046B2 (enExample) |
| KR (1) | KR20070034075A (enExample) |
| AT (1) | ATE443541T1 (enExample) |
| AU (1) | AU2005256317B2 (enExample) |
| BR (1) | BRPI0512357A (enExample) |
| CA (1) | CA2571449C (enExample) |
| DE (1) | DE602005016803D1 (enExample) |
| DK (1) | DK1768748T4 (enExample) |
| EA (1) | EA011814B1 (enExample) |
| IL (1) | IL180144A0 (enExample) |
| MX (1) | MXPA06015187A (enExample) |
| NO (1) | NO20070206L (enExample) |
| WO (1) | WO2006000224A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080118603A1 (en) * | 2006-11-21 | 2008-05-22 | Lada Mark W | Nutritional beverage for optimal bone health |
| WO2008061535A1 (en) * | 2006-11-21 | 2008-05-29 | Strontin Aps | Compositions comprising strontium and uses thereof in the treatment or prevention of gingivitis, periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal diseases. |
| ES2573327T3 (es) * | 2007-04-23 | 2016-06-07 | Baxter International Inc. | Composiciones de fibrina que contienen compuestos de estroncio |
| WO2009010305A2 (en) * | 2007-07-19 | 2009-01-22 | Dsm Ip Assets B.V. | Tablettable formulations of lipophilic health ingredients |
| US8790714B2 (en) | 2007-08-03 | 2014-07-29 | Nucitec, S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
| EP2416756A2 (en) * | 2009-04-10 | 2012-02-15 | Mahmut Bilgic | Stable pharmaceutical compositions with high bioavailibility |
| FR2945748A1 (fr) * | 2009-05-20 | 2010-11-26 | Debregeas Et Associes Pharma | Medicament a base de calcium et de vitamine d. |
| FR2953139B1 (fr) * | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| EP2591354B1 (en) * | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| EP2590965B1 (en) | 2010-07-07 | 2016-04-20 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827326B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| AU2012212385B2 (en) * | 2011-02-02 | 2015-01-15 | Ent Technologies Pty Ltd | Compositions and methods for the treatment of nasal passages |
| EP2530068A1 (en) | 2011-05-31 | 2012-12-05 | Lacer, S.A. | New strontium salts, synthesis and use thereof in the treatment of osteoporosis |
| WO2014044756A1 (en) * | 2012-09-20 | 2014-03-27 | Mokwalo SA | Strontium as anti microbial compound |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3345265A (en) * | 1963-10-09 | 1967-10-03 | Kendall & Co | Multiple layer tablet with calcium salt central core separated from soluble fluoride outer coating |
| US3699221A (en) * | 1965-02-23 | 1972-10-17 | Murray L Schole | Dental preparations |
| US3988434A (en) | 1972-08-07 | 1976-10-26 | Schole Murray L | Dental preparation |
| FR2633619B1 (fr) | 1988-06-29 | 1991-02-08 | Adir | Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant |
| FR2651497B1 (fr) | 1989-09-01 | 1991-10-25 | Adir | Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| FR2658816A1 (fr) * | 1990-02-27 | 1991-08-30 | Adir | Nouveaux sels de metaux alcalinoterreux d'oxa-polyacides leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5380530A (en) | 1992-12-29 | 1995-01-10 | Whitehill Oral Technologies | Oral care composition coated gum |
| US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
| FR2749759B1 (fr) | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
| CN1164603C (zh) | 2001-09-29 | 2004-09-01 | 南京化工大学 | 1，6－二磷酸果糖锶盐系列化合物及其制备方法和在医药中的应用 |
| FR2844797B1 (fr) | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
| FR2844796A1 (fr) | 2002-09-24 | 2004-03-26 | Servier Lab | Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
| FR2844795B1 (fr) | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates |
| PT1534305E (pt) | 2003-05-07 | 2007-02-28 | Osteologix As | Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis |
| PT1622630E (pt) | 2003-05-07 | 2012-10-11 | Osteologix As | Combinações de estrôncio para a profilaxia/tratamento de patologias da cartilagem e/ou do osso |
| US20060216358A1 (en) * | 2003-05-07 | 2006-09-28 | Christian Hansen | Controlled release composition containing a strontium salt |
-
2005
- 2005-06-24 DK DK05750580.2T patent/DK1768748T4/da active
- 2005-06-24 EP EP05750580.2A patent/EP1768748B2/en not_active Expired - Lifetime
- 2005-06-24 JP JP2007516973A patent/JP5070046B2/ja not_active Expired - Fee Related
- 2005-06-24 MX MXPA06015187A patent/MXPA06015187A/es not_active Application Discontinuation
- 2005-06-24 CA CA2571449A patent/CA2571449C/en not_active Expired - Fee Related
- 2005-06-24 EA EA200700130A patent/EA011814B1/ru active IP Right Revival
- 2005-06-24 AT AT05750580T patent/ATE443541T1/de not_active IP Right Cessation
- 2005-06-24 US US11/570,767 patent/US8658206B2/en not_active Expired - Fee Related
- 2005-06-24 AU AU2005256317A patent/AU2005256317B2/en not_active Ceased
- 2005-06-24 WO PCT/DK2005/000425 patent/WO2006000224A2/en not_active Ceased
- 2005-06-24 DE DE602005016803T patent/DE602005016803D1/de not_active Expired - Lifetime
- 2005-06-24 KR KR1020077001916A patent/KR20070034075A/ko not_active Withdrawn
- 2005-06-24 BR BRPI0512357-7A patent/BRPI0512357A/pt not_active IP Right Cessation
-
2006
- 2006-12-18 IL IL180144A patent/IL180144A0/en unknown
-
2007
- 2007-01-11 NO NO20070206A patent/NO20070206L/no not_active Application Discontinuation
-
2012
- 2012-07-13 JP JP2012157477A patent/JP2012193208A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010059239A3 (en) | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2017528507A5 (enExample) | ||
| JP2014521658A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| JP2004505052A5 (enExample) | ||
| CN103732062A (zh) | 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2012519201A5 (enExample) | ||
| JP2009513713A5 (enExample) | ||
| JP2011527687A5 (enExample) | ||
| JP2008523090A5 (enExample) | ||
| JP2005015479A (ja) | 局所麻酔薬を含有する口中用または咽頭部用製剤 | |
| JP2021503483A5 (enExample) | ||
| JP2024507367A5 (enExample) | ||
| EA011814B1 (ru) | Композиции, содержащие стронций и витамин d, и их применение | |
| TW200946142A (en) | Tablet | |
| JP2010500284A5 (enExample) | ||
| CA2641713A1 (en) | Hydrate forms of amg706 | |
| JP2010540470A5 (enExample) | ||
| JP4759102B2 (ja) | 経口投与用医薬組成物 | |
| CA2988524A1 (en) | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof | |
| TW200534852A (en) | 4-methylpyrazole formulations for inhibiting ethanol intolerance | |
| JP2017508004A5 (enExample) | ||
| JP2012511571A5 (enExample) |